Covered recipient · General Payments record
KEITH A LERRO
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$4,384.74
174 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,599.45 | 168 |
| Consulting Fee | $1,665.00 | 1 |
| Education | $120.29 | 5 |
By paying entity
PY2020 · entire year · sorted by reported total
Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KEITH A LERRO
NPI 1730161092 · CMS profile ID 169870
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
WILSON, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1730161092?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KEITH A LERRO, NPI 1730161092, CMS profile ID 169870. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730161092?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). KEITH A LERRO, NPI 1730161092, CMS profile ID 169870. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730161092?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- KEITH A LERRO, NPI 1730161092, CMS profile ID 169870, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1730161092?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
174 matching records · $4,384.74 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 174.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corporation | $15.54 | 09/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747749683 | CMS |
| Merck Sharp & Dohme Corporation | $13.41 | 09/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747757251 | CMS |
| Janssen Biotech, Inc. | $17.44 | 09/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719245089 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $16.22 | 09/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725671471 | CMS |
| Janssen Biotech, Inc. | $11.16 | 09/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719245095 | CMS |
| Genentech USA, Inc. | $11.13 | 09/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743042235 | CMS |
| Celgene Corporation | $15.24 | 09/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727865309 | CMS |
| E.R. Squibb & Sons, L.L.C. | $10.72 | 09/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727865297 | CMS |
| Lilly USA, LLC | $14.66 | 09/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728495495 | CMS |
| Seagen Inc. | $12.27 | 09/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 732440987 | CMS |
| Taiho Oncology, Inc. | $14.20 | 09/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 724401131 | CMS |
| Amgen Inc. | $12.84 | 09/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741173599 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $13.33 | 08/31/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747254247 | CMS |
| Kite Pharma, Inc. | $13.65 | 08/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 731508253 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $16.76 | 08/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 713637889 | CMS |
| Daiichi Sankyo Inc. | $13.28 | 08/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739492645 | CMS |
| Global Blood Therapeutics, Inc. | $16.94 | 08/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 742105383 | CMS |
| Incyte Corporation | $13.32 | 08/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 745790771 | CMS |
| E.R. Squibb & Sons, L.L.C. | $23.20 | 08/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727865285 | CMS |
| Dova Pharmaceuticals | $14.90 | 08/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752353431 | CMS |
| Merck Sharp & Dohme Corporation | $11.62 | 08/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747776119 | CMS |
| E.R. Squibb & Sons, L.L.C. | $20.04 | 08/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727865287 | CMS |
| GlaxoSmithKline, LLC. | $17.45 | 08/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738765283 | CMS |
| Amgen Inc. | $6.78 | 08/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741173607 | CMS |
| Genentech USA, Inc. | $15.82 | 08/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743042231 | CMS |
| GENZYME CORPORATION | $21.88 | 08/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744159093 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.98 | 08/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736333357 | CMS |
| Karyopharm Therapeutics Inc. | $16.11 | 07/31/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751735339 | CMS |
| Janssen Biotech, Inc. | $14.39 | 07/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719245077 | CMS |
| Merck Sharp & Dohme Corporation | $12.59 | 07/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747687709 | CMS |
| Epizyme, Inc., | $12.91 | 07/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 748603189 | CMS |
| AbbVie Inc. | $18.47 | 07/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721986559 | CMS |
| Eisai Inc. | $14.16 | 07/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751214357 | CMS |
| Merck Sharp & Dohme Corporation | $14.53 | 07/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747665347 | CMS |
| Agios Pharmaceuticals, Inc. | $18.25 | 07/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751964749 | CMS |
| Amgen Inc. | $14.13 | 07/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741407475 | CMS |
| Daiichi Sankyo Inc. | $18.81 | 07/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739490711 | CMS |
| GlaxoSmithKline, LLC. | $14.35 | 07/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738722163 | CMS |
| EMD Serono, Inc. | $13.19 | 07/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751282141 | CMS |
| Exelixis Inc. | $13.95 | 07/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737176149 | CMS |
| Secura Bio, Inc. | $17.74 | 07/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 733547483 | CMS |
| Coherus Biosciences Inc. | $20.37 | 07/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750864825 | CMS |
| Amgen Inc. | $15.78 | 07/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741173605 | CMS |
| Puma Biotechnology, Inc. | $15.98 | 07/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750538165 | CMS |
| Eisai Inc. | $22.33 | 06/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751343293 | CMS |
| Seagen Inc. | $11.62 | 06/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 732440911 | CMS |
| Merck Sharp & Dohme Corporation | $17.81 | 06/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747694471 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $11.49 | 06/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725667173 | CMS |
| Genentech USA, Inc. | $18.18 | 06/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743042227 | CMS |
| Daiichi Sankyo Inc. | $19.75 | 06/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739490857 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $421,529.93 | 32 |
| PY2024 | Recipient | $1,386.05 | 1 |
| PY2024 | Principal investigator | $357,799.31 | 10 |
| PY2021 | Principal investigator | $3,500.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
32 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $7,410.00 | 12/22/2025 | Non-covered Recipient Entity SARGON RESEARCH LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175336142 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $300.00 | 12/16/2025 | Non-covered Recipient Entity Sargon Research LLC | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220810320 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $175.00 | 12/15/2025 | Non-covered Recipient Entity REGIONAL MEDICAL ONCOLOGY CENTER | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190313903 |
| Principal investigator 1 | Epizyme, Inc. | $62.80 | 11/12/2025 | Non-covered Recipient Entity Regional Medical Oncology Center | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184282937 |
| Principal investigator 1 | Epizyme, Inc. | $78.00 | 11/12/2025 | Non-covered Recipient Entity Regional Medical Oncology Center | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184282939 |
| Principal investigator 1 | PFIZER INC. | $47,181.76 | 11/12/2025 | Non-covered Recipient Entity Regional Medical Onco Center | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 | No dispute reported | 06/30/2026 | 1228713154 |
| Principal investigator 1 | Exelixis Inc. | $5,000.00 | 11/06/2025 | Non-covered Recipient Entity Sargon Research LLC | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222384837 |
| Principal investigator 1 | Exelixis Inc. | $2,000.00 | 11/06/2025 | Non-covered Recipient Entity Sargon Research LLC | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222384839 |
| Principal investigator 1 | Exelixis Inc. | $5,000.00 | 11/06/2025 | Non-covered Recipient Entity Sargon Research LLC | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222384841 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,854.00 | 11/03/2025 | Non-covered Recipient Entity SARGON RESEARCH LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175336136 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $271.52 | 10/27/2025 | Non-covered Recipient Entity Regional Medical Oncology Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998925 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $119.88 | 10/27/2025 | Non-covered Recipient Entity Regional Medical Oncology Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998927 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $8.76 | 10/27/2025 | Non-covered Recipient Entity Regional Medical Oncology Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998929 |
| Principal investigator 1 | PFIZER INC. | $47,181.76 | 09/30/2025 | Non-covered Recipient Entity Regional Medical Onco Center | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 | No dispute reported | 06/30/2026 | 1228713336 |
| Principal investigator 1 | PFIZER INC. | $47,181.76 | 09/02/2025 | Non-covered Recipient Entity Regional Medical Onco Center | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 | No dispute reported | 06/30/2026 | 1228713334 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21,836.00 | 09/01/2025 | Non-covered Recipient Entity SARGON RESEARCH LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175336129 |
| Principal investigator 1 | AstraZeneca UK Limited | $18,250.00 | 08/14/2025 | Non-covered Recipient Entity SARGON RESEARCH SUMMIT LLC | phase two open label single arm trial of pirtobrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma after first line acalabrutinib progression | No dispute reported | 06/30/2026 | 1185555107 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 05/21/2025 | Non-covered Recipient Entity Sargon Research LLC | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222384833 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 05/16/2025 | Non-covered Recipient Entity Sargon Research LLC | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222384831 |
| Principal investigator 1 | Exelixis Inc. | $500.00 | 05/16/2025 | Non-covered Recipient Entity Sargon Research LLC | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222384835 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,500.00 | 03/07/2025 | Non-covered Recipient Entity Sargon Research LLC | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220810318 |
| Principal investigator 1 | Eli Lilly and Company | $163,746.93 | 01/22/2025 | Non-covered Recipient Entity SARGON RESEARCH LLC | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | No dispute reported | 06/30/2026 | 1187888242 |
| Principal investigator 1 | Exelixis Inc. | $1,250.00 | 01/10/2025 | Non-covered Recipient Entity Sargon Research LLC | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222384813 |
| Principal investigator 1 | Exelixis Inc. | $1,000.00 | 01/10/2025 | Non-covered Recipient Entity Sargon Research LLC | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222384815 |
| Principal investigator 1 | Exelixis Inc. | $18,000.00 | 01/10/2025 | Non-covered Recipient Entity Sargon Research LLC | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222384817 |
| Principal investigator 1 | Exelixis Inc. | $1,500.00 | 01/10/2025 | Non-covered Recipient Entity Sargon Research LLC | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222384821 |
| Principal investigator 1 | Exelixis Inc. | $1,043.00 | 01/10/2025 | Non-covered Recipient Entity Sargon Research LLC | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222384823 |
| Principal investigator 1 | Exelixis Inc. | $3,000.00 | 01/10/2025 | Non-covered Recipient Entity Sargon Research LLC | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222384825 |
| Principal investigator 1 | Exelixis Inc. | $650.00 | 01/10/2025 | Non-covered Recipient Entity Sargon Research LLC | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222384827 |
| Principal investigator 1 | Exelixis Inc. | $900.00 | 01/10/2025 | Non-covered Recipient Entity Sargon Research LLC | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222384829 |
| Principal investigator 1 | Eli Lilly and Company | $1,028.76 | 01/09/2025 | Non-covered Recipient Entity SARGON RESEARCH LLC | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | No dispute reported | 06/30/2026 | 1187887836 |
| Principal investigator 1 | Exelixis Inc. | $1,500.00 | 01/03/2025 | Non-covered Recipient Entity Sargon Research LLC | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1222384819 |